July 31, 2014 11:45 PM ET


Company Overview of AbGenomics International, Inc.

Company Overview

AbGenomics International, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. It offers AbGn-168, an immunomodulating investigational therapeutic antibody against CD162 that induces apoptosis of late-stage activated T cells and other immune cells, as well as spare naive, regulatory, and memory T cells; various animal disease models, such as CIA, NOD, and allergy, as well as transplantation rejection/GVHD in murine and DTH in non-human primate; and autoimmune diseases, including rheumatoid arthritis, Crohn's disease, lupus, and psoriasis. The company also provides antibody-7 ...

4984 El Camino Real

Suite 100

Los Altos, CA 94022

United States

Founded in 2000





Key Executives for AbGenomics International, Inc.

Director of Operation
Director of IP Management & Quality Assurance
Director of Project & Alliance Managements
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

AbGenomics International, Inc. Key Developments

AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM

AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States.

AbGenomics International, Inc. Raises $9.6 Million in Financing

AbGenomics International, Inc. has raised $9.6 million in a financing round in private placement.

AbGenomics International, Inc. Obtains FDA Agreement on its Phase 2 Clinical Trial Plans

AbGenomics International, Inc. announced that it has obtained agreement from U.S. Food and Drug Administration for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H. Antibody demonstrated a great safety profile in preclinical safety and phase 1 clinical trial studies in both psoriasis patients and healthy volunteers. In SRD phase 1 psoriasis patient study, a clear biological/pharmacological effect consistent with the proposed mechanism of action of AbG's antibody was demonstrated in patients. The current Phase 2 clinical trial of AbGn-168H will be a multicenter, placebo-controlled, double-blind trial. The primary objective of the study is to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect in psoriatic patients. Additional clinical trials for type-I diabetes, Crohn's and other autoimmune diseases are under evaluation.

Similar Private Companies By Industry

Company Name Region
Jackson ImmunoResearch Laboratories, Inc. United States
CardioVascular BioTherapeutics, Inc. United States
Sparta Pharmaceuticals United States
BioFlash Partners, LLC United States
Advanced Targeting Systems, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AbGenomics International, Inc., please visit www.abgenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.